Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-076-7 | CAS number: 51-03-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- October 3, 1989 - August 21, 1991
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- GLP compliance:
- yes
Test material
- Reference substance name:
- 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
- EC Number:
- 200-076-7
- EC Name:
- 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
- Cas Number:
- 51-03-6
- Molecular formula:
- C19H30O5
- IUPAC Name:
- 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- CD-1
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Duration and frequency of treatment / exposure:
- 13 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Males: 50 and 500 mg/kg
Females: 50 and 500 mg/kg
- No. of animals per sex per dose / concentration:
- Males: 15 Females: 15
- Control animals:
- yes
Results and discussion
Main ADME resultsopen allclose all
- Type:
- excretion
- Results:
- 54.76-66.16% of orally dosed radioactivity was excreted in the feces
- Type:
- excretion
- Results:
- 27.2-38.09% was excreted in the urine
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Absorbed PB appears to be quantitatively degraded since little or no parent material was found in the urine.
- Details on excretion:
- There was no meaninful difference between males and females at any dosage regimen with regard to the percent of administered dose excreted in the urine, the ratio of polar to nonpolar metabolites was greater in the male rats.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- The metabolic profile revealed that PB was extensively metabolized. Eight metabolites were isolated from urine or feces and characterized by mass spectrometry. These metabolites were formed through the oxidation and subsequent cleavage of the eather side chain and/or the methylene bridge on the benzodioxole ring.
Any other information on results incl. tables
In all tests, approximately 55 to 66% of recovered
radioactivity was found in the faeces and 27 to 39% was
found in the urine. The mean 14C-residues in tissues plus
carcass were less than 1.5% of the administered dose. No
differences were noted in the ADME pattern between males and
females, between low and high doses, or between single and
repeated dosing. Recoveries ranged from 92 to 100%.
Applicant's summary and conclusion
- Conclusions:
- No bioaccumulation potential based on study results
Based upon the results of this study, dosage patterns (quantity or number of doses) and the sex of the rat has very little or no affect on the excretion patterns of orally administered 14C Piperonyl butoxide. In addition, the data indicate that bioaccumation of piperonyl butoxide or its degradates in tissues in unlikely following oral administration of 14C piperonyl butoxide.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.